Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282984019> ?p ?o ?g. }
- W4282984019 endingPage "121927" @default.
- W4282984019 startingPage "121927" @default.
- W4282984019 abstract "This study was aimed to develop a fixed dose combination (FDC) tablet containing a low dose of evogliptin tartrate (6.87 mg) for immediate release combined with a high dose (1000 mg) of sustained-release (SR) metformin HCl appropriate for once daily dosing the treatment of type 2 diabetes. To prepare the FDC tablets, an active coating was used in this study, whereby evogliptin tartrate film was layered on a matrix core tablet containing metformin HCl. To overcome the problem caused by a low-dose drug in combination with a relatively large matrix tablet containing high-dose drug, it was also aimed to confirm the formulation and coating operation for satisfactory content uniformity, and to describe the chemical stability during storage of the amorphous active coating layer formulation in relation to molecular mobility. Furthermore, the in vitro release and in vivo pharmacokinetic profiles of metformin HCl and evogliptin tartrate in the FDC active coating tablet were compared to those of the commercially marketed reference drugs, Diabex XR® (Daewoong, Seoul, Korea) containing metformin HCl and Suganon® (Donga ST, Seoul, Korea) containing evogliptin tartrate. In conclusion, the newly developed FDC active coating tablet in this study was confirmed to be bioequivalent to the reference marketed products in beagle dogs, with satisfactory content uniformity and stability." @default.
- W4282984019 created "2022-06-17" @default.
- W4282984019 creator A5005988065 @default.
- W4282984019 creator A5028070594 @default.
- W4282984019 creator A5038815587 @default.
- W4282984019 creator A5059740015 @default.
- W4282984019 creator A5064139383 @default.
- W4282984019 creator A5065118086 @default.
- W4282984019 date "2022-07-01" @default.
- W4282984019 modified "2023-10-18" @default.
- W4282984019 title "Active coating of immediate-release evogliptin tartrate to prepare fixed dose combination tablet with sustained-release metformin HCl" @default.
- W4282984019 cites W1502077872 @default.
- W4282984019 cites W1963533328 @default.
- W4282984019 cites W1963578341 @default.
- W4282984019 cites W1963980311 @default.
- W4282984019 cites W1976787897 @default.
- W4282984019 cites W1977038312 @default.
- W4282984019 cites W1982578788 @default.
- W4282984019 cites W1984009385 @default.
- W4282984019 cites W1992932921 @default.
- W4282984019 cites W1992979358 @default.
- W4282984019 cites W1994667642 @default.
- W4282984019 cites W1997511894 @default.
- W4282984019 cites W2001522203 @default.
- W4282984019 cites W2008715843 @default.
- W4282984019 cites W2010429859 @default.
- W4282984019 cites W2011916271 @default.
- W4282984019 cites W2015335835 @default.
- W4282984019 cites W2031293048 @default.
- W4282984019 cites W2042692289 @default.
- W4282984019 cites W2043209395 @default.
- W4282984019 cites W2052637252 @default.
- W4282984019 cites W2054395311 @default.
- W4282984019 cites W2069174472 @default.
- W4282984019 cites W2069291979 @default.
- W4282984019 cites W2074558860 @default.
- W4282984019 cites W2075537424 @default.
- W4282984019 cites W2080283384 @default.
- W4282984019 cites W2091831319 @default.
- W4282984019 cites W2092536716 @default.
- W4282984019 cites W2114827436 @default.
- W4282984019 cites W2115707699 @default.
- W4282984019 cites W2117819353 @default.
- W4282984019 cites W2118816035 @default.
- W4282984019 cites W2122382827 @default.
- W4282984019 cites W2130500354 @default.
- W4282984019 cites W2146901298 @default.
- W4282984019 cites W2147774754 @default.
- W4282984019 cites W2153920846 @default.
- W4282984019 cites W2161026520 @default.
- W4282984019 cites W2166935017 @default.
- W4282984019 cites W2170640241 @default.
- W4282984019 cites W2174419428 @default.
- W4282984019 cites W2176220684 @default.
- W4282984019 cites W2318545873 @default.
- W4282984019 cites W2323149066 @default.
- W4282984019 cites W2510708214 @default.
- W4282984019 cites W2596010473 @default.
- W4282984019 cites W2602848726 @default.
- W4282984019 cites W2763089274 @default.
- W4282984019 cites W2765971788 @default.
- W4282984019 cites W2808782282 @default.
- W4282984019 cites W2886786329 @default.
- W4282984019 cites W2914024845 @default.
- W4282984019 cites W2915279136 @default.
- W4282984019 cites W2940245623 @default.
- W4282984019 cites W2955313368 @default.
- W4282984019 cites W2965470654 @default.
- W4282984019 cites W2995504956 @default.
- W4282984019 cites W3015596146 @default.
- W4282984019 cites W3026766392 @default.
- W4282984019 cites W3035805808 @default.
- W4282984019 cites W3040260316 @default.
- W4282984019 cites W4245367233 @default.
- W4282984019 cites W2013260264 @default.
- W4282984019 doi "https://doi.org/10.1016/j.ijpharm.2022.121927" @default.
- W4282984019 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35716979" @default.
- W4282984019 hasPublicationYear "2022" @default.
- W4282984019 type Work @default.
- W4282984019 citedByCount "2" @default.
- W4282984019 countsByYear W42829840192022 @default.
- W4282984019 countsByYear W42829840192023 @default.
- W4282984019 crossrefType "journal-article" @default.
- W4282984019 hasAuthorship W4282984019A5005988065 @default.
- W4282984019 hasAuthorship W4282984019A5028070594 @default.
- W4282984019 hasAuthorship W4282984019A5038815587 @default.
- W4282984019 hasAuthorship W4282984019A5059740015 @default.
- W4282984019 hasAuthorship W4282984019A5064139383 @default.
- W4282984019 hasAuthorship W4282984019A5065118086 @default.
- W4282984019 hasConcept C112705442 @default.
- W4282984019 hasConcept C126322002 @default.
- W4282984019 hasConcept C178790620 @default.
- W4282984019 hasConcept C185592680 @default.
- W4282984019 hasConcept C192562407 @default.
- W4282984019 hasConcept C2777699559 @default.
- W4282984019 hasConcept C2779306644 @default.
- W4282984019 hasConcept C2780323712 @default.
- W4282984019 hasConcept C2781448156 @default.